Table 1.
Association of DOT1L expression with the clinicopathological features of patients with borderline and malignant ovarian tumors
| Characteristics | Sample | DOT1L expression | χ 2 | P | |
|---|---|---|---|---|---|
| Low expression | High expression | ||||
| Age at diagnosis | 235 | 0.120 | 0.729 | ||
| ≤50 | 114 | 51 (44.7%) | 63 (55.3%) | ||
| >50 | 117 | 55 (47.0%) | 62 (53.0%) | ||
| Unknown | 4 | ||||
| FIGO stage | 235 | 17.655 | 0.001 | ||
| I | 20 | 18 (90.0%) | 2 (10.0%) | ||
| II | 17 | 8 (47.1%) | 9 (52.9%) | ||
| III | 159 | 66 (41.5%) | 93 (58.5%) | ||
| IV | 29 | 11 (37.9%) | 18 (62.1%) | ||
| Unknown | 10 | ||||
| Histologic grade | 235 | 8.831 | 0.012 | ||
| Grade 1 | 40 | 27 (67.5%) | 13 (32.5%) | ||
| Grade 2 | 58 | 24 (41.4%) | 34 (58.6%) | ||
| Grade 3 | 120 | 50 (41.7%) | 70 (58.3%) | ||
| Unknown | 17 | ||||
| Ascites | 235 | 0.005 | 0.944 | ||
| Yes | 173 | 78 (45.1%) | 95 (54.9%) | ||
| No | 36 | 16 (44.4%) | 20 (55.6%) | ||
| Unknown | 26 | ||||
| LN metastasis | 235 | 4.392 | 0.036 | ||
| Yes | 73 | 29 (39.7%) | 44 (60.3%) | ||
| No | 106 | 59 (55.7%) | 47 (44.3%) | ||
| Unknown | 56 | ||||
| Preoperative CA125 (U/ml) | 235 | 1.829 | 0.176 | ||
| ≤600 | 68 | 33 (48.5%) | 35 (51.5%) | ||
| >600 | 80 | 30 (37.5%) | 50 (62.5%) | ||
| Unknown | 87 | ||||